Low-Dose Doxepin: Awake Minutes and Early-Morning Sleep

Time awake and awakening counts can change differently

In a 2010 trial¹ of 240 older adults, mean age 71, participants took 1 mg or 3 mg of doxepin, or placebo, nightly for 12 weeks. About 65% were women.¹

On laboratory night 85, people assigned 3 mg spent a mean 75.7 minutes awake after sleep began, compared with 109.2 minutes on placebo. The proportion of the final quarter of the night spent asleep also improved.¹

Yet neither dose significantly reduced awakening counts compared with placebo. Spending less time awake after an awakening can improve sleep even when awakenings still occur. This study’s benefit should not be described as sleeping without waking.¹

The adult trial found a similar maintenance pattern

A 2011 trial² randomized 229 adults aged 18 to 64; 221 received treatment. They took 3 mg, 6 mg or placebo for 35 nights.²

On laboratory night 29, mean time awake after sleep began was 47.2 minutes with 3 mg, 40.7 with 6 mg and 60.5 with placebo. Awakening counts again did not differ significantly. Both doses improved recorded sleep onset on the first night, but that advantage was not significant at later assessments.²

Somaxon funded both trials. Both selected people with primary insomnia, so findings may not extend to complex medical conditions.¹²

Laboratory tests cannot guarantee next-day safety

The adult trial found no significant next-day impairment on its test battery. The authors nevertheless noted that balance and sustained attention were not assessed.²

Silenor’s U.S. label still warns about next-day impairment and advises against driving until fully awake. It prohibits alcohol use with the medicine. Its 3 mg and 6 mg tablets are indicated for difficulty staying asleep; larger doxepin doses require their own prescribing assessment.³

Match the treatment goal to the sleep problem

The 2025 VA/DoD guideline suggests CBT-I over medication as initial treatment for chronic insomnia. When a medication course is offered, doxepin is among the options receiving a weak recommendation. The guideline advises discussing a plan for stopping medication when starting short-term treatment.⁴

Ask what improvement you are aiming for: returning to sleep sooner, spending less of the early morning awake, or functioning better the next day. Bring notes about those experiences and any morning drowsiness. The Silenor label calls for reassessment if insomnia persists after seven to ten days of treatment.³

The “Medicines Belong in Shared Decisions” section of Did I Do That in My Sleep? covers expected benefit, interactions, next-day effects and review plans. Our doxepin bedtime-details guide covers product and meal-timing instructions separately.